Best Value Stocks to Buy for April 8th
QFIN, NMRK and FRO made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 8, 2025.
All You Need to Know About Frontline (FRO) Rating Upgrade to Strong Buy
Frontline (FRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Income Stocks to Buy for April 4th
HSNGY, FRO and TEF made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 4, 2025.
Best Income Stocks to Buy for April 1st
FRO, IX and UVSP made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 1, 2025.
Best Value Stocks to Buy for April 1st
FRO, SAN and IX made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 1, 2025.
Should Value Investors Buy FRONTLINE PLC (FRO) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing FRONTLINE PLC (FRO) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML
Represents first ever triplet combination using targeted radiotherapy as a backbone therapy in AML with initial clinical data expected in 2H:2025 Expansion into frontline setting greatly expands potential addressable patient opportunity for Actimab-A Triplet combination supported by previously completed Phase 1 trials of Actimab-A + Venetoclax and Actimab-A + CLAG-M demonstrating Actimab-A's mutation agnostic and synergistic potential NEW YORK , March 11, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first clinical trial under its previously announced Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for Actimab-A has been initiated. The trial (NCT06802523) will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients.
Win-Win Momentum Plays With Strong Dividend Yields
Whether deserved or not, dividend stocks have a reputation for being somewhat boring—sturdy and dependable, but in low-growth industries or comprising companies that are well beyond their days of rapid share price gains. Though dividend stocks are not necessarily safe in all cases, they have a reputation for being a strong defensive play.
Frontline Plc (FRO) Q4 2024 Earnings Call Transcript
Frontline Plc (NYSE:FRO ) Q4 2024 Earnings Conference Call February 28, 2025 9:00 AM ET Company Participants Lars Barstad - Chief Executive Officer Inger Klemp - Chief Financial Officer Conference Call Participants Jonathan Chappell - Evercore ISI Omar Nokta - Jefferies Sherif Elmaghrabi - BTIG Lars Barstad Thank you very much, dear all, and thank you for dialing into Frontline's quarterly earnings call. Being in the tanker industry, one is used to evolving and ever changing markets, largely affected by geopolitical events, but it's becoming a little bit exhausting having potential seismic shifts by the hour.
Analysts Estimate Frontline (FRO) to Report a Decline in Earnings: What to Look Out for
Frontline (FRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib
